Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical Thalidomide for Oral Lesions in HIV/AIDS Patients
NCT00001524Phase 2Completed
- Sponsor
- National Institute of Dental and Craniofacial Research
- Start
- Jun 1996
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of thalidomide in oral lesions and burning mouth syndrome (BMS) (3 arms), sponsored by National Institute of Dental and Craniofacial Research. Primary endpoints: Healing of oral lesions at 8 weeks and Pain assessment at 8 weeks. Started Jun 1996; status: completed.
02
Drugs
thalidomide
03
Conditions
oral lesionsburning mouth syndrome (BMS)
Beyond the preview
Go deeper on NCT00001524.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00001524.